| Cat.No. | Name | Information |
|---|---|---|
| M1672 | BI 2536 | BI 2536 is a novel, highly selective, potent dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. |
| M49476 | CYC-800 | CYC-800 is a PLK1 inhibitor that can be used in tumor-related studies. |
| M49475 | SOL-686 | SOL-686 is a PLK1 inhibitor that can be used in glioma-related studies. |
| M49474 | BAL0891 | BAL0891 is a potential first-in-class PLK1/TTK inhibitor with antiproliferative activity for studies related to solid tumors. |
| M49473 | Plogosertib | Plogosertib is a selective, potent, orally active, ATP-competitive PLK1 inhibitor with an IC50 value of 3 nM.In addition, Plogosertib exhibits antiproliferative and anticancer activity and can be used in a variety of tumor studies. |
| M41581 | PLK1-IN-5 | PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. |
| M41580 | PLK1-IN-6 | PLK1-IN-6 is a potent and selective PLK1 inhibitor, with an IC50 of 0.45 nM. |
| M38942 | Dihydrobaicalein | Dihydrobaicalein is a PLK1 Inhibitor with an IC50 of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens. |
| M30482 | Poloppin | Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC50=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (Kd= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors. |
| M30051 | Cyclapolin 9 | Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC50 of 500 nM. Cyclapolin 9 is inactive against other kinases. |
| M28838 | Poloxime | Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity. |
| M27875 | CFI-400437 | CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM). |
| M20215 | WAY-619275 | WAY-619275 improving mRNA splicing |
| M13721 | TAK-960 dihydrochloride | TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. |
| M8358 | Poloxin | Poloxin is a non-ATP competitive Polo-like Kinase 1 (Plk1) inhibitor that targets the polo-box domain. |
| M7645 | BTO-1 | BTO-1 is a polo-like kinase (Plk) inhibitor. |
| M7350 | TAK 960 hydrochloride | TAK 960 hydrochloride is a potent PLK1 inhibitor (IC50 values are 0.8, 16.9 and 50.2 nM for PLK1, PLK2 and PLK3 respectively). Exhibits >20-fold selectivity for PLK1 over FAK, MLCK and FES, and has minimal activity against a panel of 282 other kinases. |
| M6577 | Centrinone B | Centrinone B is a high affinity and selective PLK4 inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
